TGTPG GP A, LLC
Institutional investor · Portfolio as of Q1 2026
Top Holdings76 positions
LIFESTANCE HEALTH GROUP INC | 140M | $892M | 24.2% | $9.52 | -33.09% | 18 qtrssince 2021-Q4 | Decreased 0 |
JACKSON FINANCIAL INC | 4.7M | $498.5M | 13.6% | $104.15 | 0.00% | 1 qtr | New 97 |
LIFE TIME GROUP HOLDINGS INC | 17.8M | $480.4M | 13.1% | $17.21 | +56.54% | 18 qtrssince 2021-Q4 | Unchanged 0 |
SIONNA THERAPEUTICS INC | 6.5M | $260.4M | 7.1% | $11.60 | +245.66% | 5 qtrssince 2025-Q1 | Decreased 0 |
BETA TECHNOLOGIES INC | 16.4M | $241M | 6.6% | $28.21 | -47.89% | 2 qtrssince 2025-Q4 | Unchanged 0 |
AMNEAL PHARMACEUTICALS INC | 12.3M | $153.2M | 4.2% | $4.79 | +159.50% | 18 qtrssince 2021-Q4 | Unchanged 0 |
NGL ENERGY PARTNERS LP | 5.9M | $73.2M | 2.0% | $12.33 | 0.00% | 1 qtr | New 68 |
CERIBELL INC | 4M | $72.7M | 2.0% | $25.86 | -29.12% | 6 qtrssince 2024-Q4 | Unchanged 0 |
ENVIRI CORP | 3.6M | $70.9M | 1.9% | $19.62 | +11.88% | 1 qtr | New 68 |
| 56.6M | $67.7M | 1.8% | — | — | — | New 68 | |
BICARA THERAPEUTICS INC | 3M | $59.9M | 1.6% | $25.44 | — | 7 qtrssince 2024-Q3 | Unchanged 0 |
| 40M | $54M | 1.5% | — | — | — | New 67 | |
| 46.3M | $47M | 1.3% | — | — | 1 qtr | New 67 | |
BRUKER CORP | 163,000 | $47M | 1.3% | $36.06 | 0.00% | 1 qtr | New 67 |
ALLOGENE THERAPEUTICS INC | 18.7M | $45.7M | 1.2% | $14.92 | -83.65% | 18 qtrssince 2021-Q4 | Unchanged 0 |
| 43M | $44.5M | 1.2% | — | — | — | New 67 | |
| 34M | $42.1M | 1.1% | — | — | — | New 67 | |
| 575,000 | $37.3M | 1.0% | — | — | — | New 66 | |
Quanex Building Products Corp | 2.1M | $36.9M | 1.0% | $17.82 | 0.00% | 1 qtr | New 66 |
NOVANTA INC | 661,667 | $35.4M | 1.0% | $118.11 | 0.00% | 1 qtr | New 57 |
TPG GP A, LLC manages $3.7B across 76 positions as of Q1 2026. Top holdings: LFST (24.2%), JXN (13.6%), LTH (13.1%). Fund DNA: Momentum Trader. HoldingsIntel Score: 1.5/5.0.
Active quarter - 67 new positions, 1 exits, 0 increased. Top move: JXN (NEW, conviction 97). Portfolio: $3.7B across 76 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
No active accumulation streaks detected for this filer.
Streaks require 2+ consecutive quarters of increased positions in the most recent period.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR